戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ther these are causally linked, ideally in a double-blind placebo-controlled trial.
2 n 24 h of AHF presentation in a prospective, double blind, placebo-controlled trial.
3 mbers of doses to 3 at 8-week intervals in a double blind, placebo-controlled trial.
4 s of doses to three at 8-week intervals in a double blind, placebo-controlled trial.
5  doxycyline in a pre-registered, randomised, double-blind, placebo-controlled trial.
6 ght and obesity.This study was a randomized, double-blind, placebo-controlled trial.
7                                   This was a double-blind, placebo-controlled trial.
8 dystrophinopathy, we conducted a randomized, double-blind, placebo-controlled trial.
9 (teriparatide) or placebo for 18 months in a double-blind, placebo-controlled trial.
10 f patients with frequent episodes of IA in a double-blind, placebo-controlled trial.
11     IBIS-II is an international, randomised, double-blind, placebo-controlled trial.
12 ding (HALT-IT): an international randomised, double-blind, placebo-controlled trial.
13        This was a single-centre, randomized, double-blind, placebo-controlled trial.
14 rder (BED) was evaluated in two multicenter, double-blind, placebo-controlled trials.
15                       We did two randomised, double-blind, placebo-controlled trials.
16 nse to anifrolumab may be examined in larger double-blind, placebo-controlled trials.
17 ertiary HPS unit were randomly assigned in a double-blinded, placebo-controlled trial.
18                       In a pilot randomized, double-blind, placebo-controlled trial, 100 mg of DCS or
19                                      In this double-blind, placebo-controlled trial, 120 asymptomatic
20                          In this randomized, double-blind, placebo-controlled trial, 18- to 50-year-o
21                              In a randomised double-blind, placebo controlled trial, 22 early onset P
22           In this single-centre, randomised, double blind, placebo-controlled trial, 31 patients with
23                             In a randomised, double-blind, placebo-controlled trial, 40 HIV-infected
24                     In this 2 x 2 factorial, double-blind placebo-controlled trial, 457 lead-exposed
25  (BLP).Methods: In this phase I, randomized, double-blind, placebo-controlled trial, 48 healthy volun
26                          In this randomized, double-blind, placebo-controlled trial, 50 patients with
27                       In a 24-wk randomized, double-blinded, placebo-controlled trial, 622 participan
28                          In this randomized, double-blind, placebo-controlled trial, 94 preterm infan
29 n this prospective, multicenter, randomized, double-blind, placebo-controlled trial, 96 HT recipients
30                   We conducted a randomized, double-blind, placebo-controlled trial across the United
31         For this international, multicentre, double-blind, placebo-controlled trial, adult patients (
32           In this single-centre, randomised, double-blind, placebo-controlled trial, adult patients (
33             In this multicentre, randomised, double-blind, placebo-controlled trial, adults (>/=18 ye
34                          In this randomised, double-blind, placebo-controlled trial, adults with pred
35  incidence of herpes zoster in a randomized, double-blind, placebo-controlled trial among 3408 person
36           We conducted a 2-year, randomized, double-blinded, placebo-controlled trial among 2727 hous
37 ther well-designed and statistically powered double-blind, placebo-controlled trials are needed.
38                This exploratory, randomized, double-blind, placebo-controlled trial assessed a preemp
39                             This randomized, double-blind, placebo-controlled trial assessed the effe
40 cquisition among women in VOICE, randomized, double-blinded, placebo-controlled trial assessing daily
41                      REWIND is a randomised, double-blind placebo-controlled trial at 371 sites in 24
42  Preschoolers (SHIP) Study was a randomised, double-blind, placebo-controlled trial at 25 cystic fibr
43        REWIND was a multicentre, randomised, double-blind, placebo-controlled trial at 371 sites in 2
44                          In this randomised, double-blind, placebo-controlled trial at 590 sites in 4
45 We did a multicentre, phase 2/3, randomised, double-blind, placebo-controlled trial at 92 sites in th
46                      We did a single-centre, double-blind, placebo-controlled trial at the Glasgow Cl
47                         We did a randomised, double-blind, placebo-controlled trial at the Thai Red C
48                         We did a randomised, double-blind, placebo-controlled trial at three centres
49                     We did a large, phase 2, double-blind, placebo-controlled trial at three sites in
50                         We did a randomised, double-blind, placebo-controlled, trial at 32 health cen
51                                              Double-blinded, placebo-controlled trial at 9 academic m
52                      We did this randomised, double-blind, placebo-controlled trial between Dec 15, 2
53                          In this randomised, double-blind, placebo-controlled trial, boys from three
54                                           In double-blind, placebo-controlled trials, budesonide-form
55      We performed our study as a randomized, double-blind, placebo-controlled trial by training other
56 ted in a phase III, multicenter, randomized, double-blind, placebo-controlled trial (clinical.govNCT0
57                            This multicenter, double-blind, placebo-controlled trial compared the effe
58 ual Antiplatelet Therapy Study, a randomized double-blind, placebo-controlled trial, compared 30 vers
59           METHODS AND TIME was a randomized, double-blind, placebo-controlled trial comparing 150 mil
60           ODYSSEY OUTCOMES was a randomized, double-blind, placebo-controlled trial comparing alirocu
61      International, multicenter, randomized, double-blinded, placebo-controlled trial comparing exten
62  of asthma, were included in the randomized, double-blind, placebo-controlled trial, comprising 3 yea
63 f the evidence varies considerably, with few double-blind placebo-controlled trials conducted.
64 (SNPs) in 2259 participants in a randomized, double-blind, placebo-controlled trial conducted at 11 c
65                         Phase 3, randomized, double-blind, placebo-controlled trial conducted at 18 s
66 TING, AND PARTICIPANTS: Phase 3, randomized, double-blind, placebo-controlled trial conducted at 31 s
67                     Multicenter, randomized, double-blind, placebo-controlled trial conducted between
68                                         In a double-blind, placebo-controlled trial conducted from 19
69                                  Randomized, double-blind, placebo-controlled trial conducted in 13 F
70 tal Asthma Reduction Trial was a randomized, double-blind, placebo-controlled trial conducted in 3 ce
71                     Multicenter, randomized, double-blind, placebo-controlled trial conducted in 3 Sp
72 rdio was a phase 3, multicenter, randomized, double-blind, placebo-controlled trial conducted in 720
73                             In a randomized, double-blind, placebo-controlled trial conducted in Euro
74 rican Region with Malaria) was a randomized, double-blinded, placebo-controlled trial conducted in ma
75 GN, SETTING, AND PARTICIPANTS: A randomized, double-blind, placebo-controlled trial, conducted at 190
76                                      In this double-blind, placebo-controlled trial (DELIGHT), we enr
77 n recruited to the AIMS trial, a randomised, double-blind, placebo-controlled trial designed to evalu
78     Patients with NAFLD were randomised in a double blind placebo-controlled trial [DHA+EPA(n=51), pl
79            Part 1 consisted of a randomised, double-blind, placebo-controlled trial done over 18 mont
80           ODYSSEY OUTCOMES was a randomised, double-blind, placebo-controlled trial, done at 1315 sit
81 ion Study (THEMIS) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 s
82               Two international, randomized, double-blind, placebo-controlled trials (DUAL-1, DUAL-2)
83  in an age-dependent fashion in a randomized double-blind placebo-controlled trial (Effects of Psycho
84                                A randomized, double-blind, placebo-controlled trial (Effects of Psych
85                    In this first randomized, double-blind, placebo-controlled trial, enoxaparin (40 m
86                       A phase 1-2 randomized double-blind placebo-controlled trial enrolled 252 parti
87                      METHODS AND Randomized, double-blinded, placebo-controlled trial enrolled 31 pat
88                                  Randomized, double-blinded, placebo-controlled trial enrolled 31 pat
89                                         In a double-blind, placebo-controlled trial enrolling females
90                                   A phase 2, double-blind, placebo-controlled trial evaluated apremil
91        Two identically designed, randomized, double-blind, placebo-controlled trials evaluated the ef
92 NIZE was a phase 3, multicenter, randomized, double-blind, placebo-controlled trial evaluating zircon
93                 In this phase 3, randomised, double-blind, placebo-controlled trial (EXPLORER-HCM) in
94   The authors conducted a 16-week randomized double-blind placebo-controlled trial for geriatric depr
95                 Pooled data from randomized, double-blind, placebo-controlled trials for the clinical
96                  We performed a multicenter, double-blind, placebo-controlled trial, from March 2016
97             Following up these findings in a double-blind placebo controlled trial in nondiabetic hea
98                    We conducted a randomized double-blind placebo-controlled trial in patients underg
99          We conducted a phase 2, randomized, double-blind, placebo-controlled trial in 27 centers acr
100                   We conducted a randomized, double-blind, placebo-controlled trial in 740 schoolchil
101                We undertook this randomised, double-blind, placebo-controlled trial in a general adul
102                      We did this randomised, double-blind, placebo-controlled trial in antenatal clin
103                                              Double-blind, placebo-controlled trial in HIV+ with CD4(
104 eworming, we conducted a cluster-randomized, double-blind, placebo-controlled trial in Indonesia and
105                For this pragmatic randomised double-blind, placebo-controlled trial in Khayelitsha, S
106                                         In a double-blind, placebo-controlled trial in Niger, we rand
107 -of-concept study consisted of a randomised, double-blind, placebo-controlled trial in patients with
108    VOYAGER PAD was a phase 3, international, double-blind, placebo-controlled trial in patients with
109 y on inflammation and immune activation in a double-blind, placebo-controlled trial in PWH at moderat
110 a population-based, individually randomised, double-blind, placebo-controlled trial in the Brong Ahaf
111 with ASD who have GI problems, and warrant a double-blind, placebo-controlled trial in the future.
112                   We conducted a randomized, double-blind, placebo-controlled trial in treatment-naiv
113          We undertook a phase 3, randomised, double-blind, placebo-controlled trial in two children's
114                      We did this randomised, double-blind, placebo-controlled trial in two tertiary-c
115 ineraux Antioxydants study was a randomized, double-blind, placebo-controlled trial in which particip
116                       This was a randomized, double-blind, placebo-controlled trial in which patients
117                   We performed a randomized, double-blind, placebo-controlled trial in which, after p
118 arypox virus (ALVAC) primes in 2 randomized, double-blind, placebo-controlled trials in southern Afri
119                              We reanalyzed 2 double-blind, placebo-controlled trials in unmedicated m
120                             This randomized, double-blind, placebo-controlled trial included patients
121             METHOD: This 6-week, randomized, double-blind, placebo-controlled trial included patients
122                             This randomized, double-blind, placebo-controlled trial involved a total
123          This was a multicenter, randomized, double-blind, placebo-controlled trial involving 17 hosp
124 nt Sertraline Trial (CAST) was a randomized, double-blind, placebo-controlled trial involving 201 pat
125                   We conducted a randomized, double-blind, placebo-controlled trial involving 27,564
126                   We conducted a randomized, double-blind, placebo-controlled trial involving 30,449
127 ucted an investigator-initiated, randomized, double-blind, placebo-controlled trial involving 308 pat
128                             In a randomized, double-blind, placebo-controlled trial involving 84,496
129                   We performed a randomized, double-blind, placebo-controlled trial involving human i
130      We conducted a multicenter, randomized, double-blind, placebo-controlled trial involving patient
131                    FOURIER was a randomized, double-blind, placebo-controlled trial involving patient
132                   We performed a randomized, double-blind, placebo-controlled trial involving patient
133      We performed a multicenter, randomized, double-blind, placebo-controlled trial involving patient
134  semaglutide in an event-driven, randomized, double-blind, placebo-controlled trial involving patient
135                     We performed randomized, double-blind, placebo-controlled trials involving adults
136                                      In this double-blind, placebo-controlled trial, nondiabetic HFrE
137   The authors conducted an 8-week randomized double-blind placebo-controlled trial of adjunctive test
138                              This randomized double-blind placebo-controlled trial of adult outpatien
139 ew Guinea (PNG) participated in a randomised double-blind placebo-controlled trial of blood- plus liv
140 elafibranor in an international, randomized, double-blind placebo-controlled trial of patients with n
141              This was a multisite randomized double-blind placebo-controlled trial of ultra-low-dose
142 o feeding study, nested within a randomized, double-blind, placebo-controlled trial of 141 adults wit
143                 A single-center, randomized, double-blind, placebo-controlled trial of 153 patients u
144                We performed a single-center, double-blind, placebo-controlled trial of 2 separate coh
145                  We performed a prospective, double-blind, placebo-controlled trial of 449 consecutiv
146 ebo in 30 cases), we performed a randomized, double-blind, placebo-controlled trial of 5 days of 80 m
147       At a single site, we did a randomised, double-blind, placebo-controlled trial of a monovalent i
148          We conducted a phase 3, randomized, double-blind, placebo-controlled trial of a monthly vagi
149              An ongoing phase 2, randomised, double-blind, placebo-controlled trial of a TDV is being
150      We performed a prospective, randomized, double-blind, placebo-controlled trial of adults with eo
151                   We conducted a randomized, double-blind, placebo-controlled trial of amitriptyline
152              Here we report on a randomized, double-blind, placebo-controlled trial of an oral synbio
153                   We performed a randomized, double-blind, placebo-controlled trial of anastrozole in
154                         We did a randomised, double-blind, placebo-controlled trial of canakinumab in
155 ples from subjects enrolled in a randomized, double-blind, placebo-controlled trial of Cat-PAD, we em
156        We conducted a randomized, multisite, double-blind, placebo-controlled trial of daily 1760 mcg
157                   We performed a randomized, double-blind, placebo-controlled trial of DAR-0100A (15
158          The Dex-CSDH trial is a randomised, double-blind, placebo-controlled trial of dexamethasone
159 ervals in a substudy of iPrEx, a randomized, double-blind, placebo-controlled trial of FTC/TDF PrEP.
160  disorder enrolled in an 8-week, randomized, double-blind, placebo-controlled trial of guanfacine plu
161  D Assessment (ViDA) Study was a randomised, double-blind, placebo-controlled trial of healthy volunt
162 riori substudy of a multicenter, randomized, double-blind, placebo-controlled trial of hydrocortisone
163           We did an individually randomised, double-blind, placebo-controlled trial of infants born i
164 en in Crisis (MAGiC) study was a randomized, double-blind, placebo-controlled trial of intravenous ma
165 were also eligible for a nested, randomised, double-blind, placebo-controlled trial of MVA-BN-Filo.
166                    In this first randomized, double-blind, placebo-controlled trial of omalizumab in
167 esistance Intervention After Stroke trial, a double-blind, placebo-controlled trial of pioglitazone f
168     To test this, we conducted a randomized, double-blind, placebo-controlled trial of pioglitazone t
169         We performed a 12-month, randomized, double-blind, placebo-controlled trial of pomegranate ju
170                   We conducted a randomized, double-blind, placebo-controlled trial of pregabalin in
171                                  Randomized, double-blind, placebo-controlled trial of single dose re
172  these nutrients, we conducted a randomized, double-blind, placebo-controlled trial of supplementatio
173                             In a randomized, double-blind, placebo-controlled trial of tenofovir diso
174 0 mf/mL blood were enrolled in a randomized, double-blind, placebo-controlled trial of the humanized
175 mycin Efficacy and Safety) trial: a 48-week, double-blind, placebo-controlled trial of thrice-weekly
176 participants in the BLESS trial, a 12-month, double-blind, placebo-controlled trial of twice-daily er
177 VDAART), a well-conducted large, randomized, double-blind, placebo-controlled trial of vitamin D supp
178  D Assessment (ViDA) study was a randomized, double-blind, placebo-controlled trial of vitamin D supp
179                       This was a randomised, double-blind, placebo-controlled trial of vitamin D(3) s
180                         We did a randomised, double-blind, placebo-controlled trial of vitamin D3 sup
181  (TRA 2 degrees P-TIMI 50) was a randomized, double-blind, placebo-controlled trial of vorapaxar in 2
182 hemic Events-TIMI 50 trial was a randomized, double-blind, placebo-controlled trial of vorapaxar in p
183 0 (TRA2 degrees P-TIMI 50) was a randomized, double-blind, placebo-controlled trial of vorapaxar in s
184 arction 50) was a multinational, randomized, double-blind, placebo-controlled trial of vorapaxar in s
185  were pooled from two phase III, randomized, double-blind, placebo-controlled trials of IFN-gamma-1b
186              This review analyzed randomized double-blind, placebo-controlled trials of molecularly t
187 m inception to Jan 31, 2016, for randomised, double-blind, placebo-controlled trials of second-genera
188                             We completed two double-blind, placebo-controlled trials of SNRI antidepr
189    We conducted two multicenter, randomized, double-blind, placebo-controlled trials of subcutaneous
190                        Data from randomized, double-blind, placebo-controlled trials of Timothy grass
191      We conducted three phase 3, randomized, double-blind, placebo-controlled trials of tofacitinib t
192 We report findings from a 12-week randomized double-blinded placebo-controlled trial of methylphenida
193                   We performed a randomized, double-blinded, placebo-controlled trial of 5,110 adults
194                   We performed a randomized, double-blinded, placebo-controlled trial of 5110 adults
195                   We conducted a randomized, double-blinded, placebo-controlled trial of a replicatio
196 rom women who were enrolled in a randomized, double-blinded, placebo-controlled trial of vitamin D su
197  vs placebo has been clearly demonstrated, a double-blind placebo-controlled trial on the effect of l
198                            In a multicenter, double-blind, placebo-controlled trial, participants pre
199 stigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial, patients who had
200                          In this randomised, double-blind, placebo-controlled trial, patients with a
201                           In this phase III, double-blind, placebo-controlled trial, patients with ch
202           In this single-centre, randomised, double-blind, placebo-controlled trial, patients with mo
203                 Patients and Methods In this double-blinded, placebo-controlled trial, patients with
204 nt Ethyl-Intervention Trial), a multicenter, double-blind, placebo-controlled trial, randomly assigne
205 and Safety Cardiovascular Outcomes Trial), a double-blind, placebo-controlled trial, randomly assigne
206  magnetic resonance imaging to a randomized, double-blind, placebo-controlled trial (RCT) of antidepr
207                             This randomized, double-blind, placebo-controlled trial recruited patient
208      This PreSERVE-AMI (Phase 2, randomized, double-blind, placebo-controlled trial) represents the l
209 hysicians' Health Study II was a randomized, double-blind, placebo-controlled trial testing multivita
210                   We performed a randomized, double-blind, placebo-controlled trial testing the effec
211 ) study, a phase 3, multicenter, randomized, double-blind, placebo-controlled trial that enrolled 301
212         We conducted a randomized, adaptive, double-blind, placebo-controlled trial that enrolled pat
213  proof-of-concept study (POC) was an 8-week, double-blind, placebo-controlled trial that evaluated LY
214           SOLID-TIMI 52 was a multinational, double-blind, placebo-controlled trial that randomized 1
215  Vitamin D Assessment Study is a randomized, double-blind, placebo-controlled trial that recruited pa
216                                A randomized, double-blind, placebo-controlled trial that used a 2 x 2
217                                 There were 7 double-blind, placebo-controlled trials that were rated
218                           For maintenance, 6 double-blind, placebo-controlled trials that were rated
219                             In a randomized, double-blind, placebo-controlled trial (the Dietary Inte
220       We designed a multicenter, randomized, double-blind, placebo-controlled trial (the SUGAR-DM-HF
221              We did an 18-month, randomised, double-blind, placebo-controlled trial (TIRCON2012V1), f
222                      The authors conducted a double-blind placebo-controlled trial to assess whether
223            We performed the first randomized double-blind placebo-controlled trial to evaluate effica
224 alyzed data from 1092 patients enrolled in a double-blind placebo-controlled trial to evaluate the ef
225 a, the authors conducted a 6-week randomized double-blind placebo-controlled trial to investigate the
226                               We conducted a double-blind, placebo-controlled trial to assess the eff
227                   We conducted a randomized, double-blind, placebo-controlled trial to assess whether
228          We conducted a phase 3, randomized, double-blind, placebo-controlled trial to confirm the ef
229                   We performed a randomized, double-blind, placebo-controlled trial to determine whet
230      We conducted a multicenter, randomized, double-blind, placebo-controlled trial to evaluate proge
231                               We performed a double-blind, placebo-controlled trial to evaluate the e
232                   We performed a randomized, double-blind, placebo-controlled trial to evaluate the e
233                               We conducted a double-blind, placebo-controlled trial to evaluate the e
234        We performed a phase IIb, randomized, double-blind, placebo-controlled trial to evaluate the e
235          We conducted a 24-week, randomized, double-blind, placebo-controlled trial to evaluate the e
236 R-HCM is a multicenter, phase 3, randomized, double-blind, placebo-controlled trial to investigate th
237                   We conducted a randomized, double-blind, placebo-controlled trial to investigate th
238                               We conducted a double-blind, placebo-controlled trial to investigate wh
239                    We conducted a randomized double-blinded placebo-controlled trial to determine the
240               This is an ongoing randomized, double-blinded, placebo-controlled trial to evaluate the
241                                REMOVAL was a double-blind, placebo-controlled trial undertaken at 23
242                                      In this double-blind, placebo-controlled trial, undertaken acros
243             Phase 2 randomized, multicenter, double-blind, placebo-controlled trial using a sequentia
244 DeltaNS2/Delta1313/I1314L was evaluated in a double-blind, placebo-controlled trial (vaccine-placebo
245                             This randomized, double-blind, placebo-controlled trial was carried out i
246                       Methods: A randomized, double-blind, placebo-controlled trial was conducted at
247                              This randomized double-blind, placebo-controlled trial was conducted bet
248                     A factorial, randomized, double-blind, placebo-controlled trial was conducted in
249                                 A randomized double-blind, placebo-controlled trial was conducted in
250                                A randomized, double-blind, placebo-controlled trial was conducted in
251        From March 2014 through March 2017, a double-blind, placebo-controlled trial was conducted in
252                This multicentre, randomised, double-blind, placebo-controlled trial was done at 371 s
253                    This phase 2, randomised, double-blind, placebo-controlled trial was done in 72 ba
254                This multicenter, randomized, double-blind, placebo-controlled trial was performed at
255                                A randomized, double-blind, placebo-controlled trial was performed in
256                       A phase 3, randomized, double-blind, placebo-controlled trial was performed to
257                             This randomised, double-blind, placebo-controlled trial was planned for 4
258                  The aim of this randomized, double-blind, placebo-controlled trial was to test the e
259                                This phase 3, double-blind, placebo-controlled trial was undertaken at
260                This multicentre, randomised, double-blind, placebo-controlled trial was undertaken at
261                                A randomized, double-blind, placebo-controlled trial was used.
262 t ventricular ejection fraction <50% from 10 double-blind, placebo-controlled trials was performed.
263                          In this randomised, double-blind, placebo-controlled trial we recruited part
264 Day 14.Methods: In a multicenter, randomized double-blind placebo-controlled trial, we studied retrea
265                 In this phase 3, randomized, double-blind, placebo-controlled trial, we assigned 5050
266             In this multicenter, randomized, double-blind, placebo-controlled trial, we assigned prev
267                In a multicenter, randomized, double-blind, placebo-controlled trial, we compared alef
268                                In a 50-week, double-blind, placebo-controlled trial, we compared meth
269                 In this phase 2, randomized, double-blind, placebo-controlled trial, we compared subc
270                   In the GRAVITAS randomised double-blind, placebo-controlled trial, we enrolled adul
271                In a prospective, randomized, double-blind, placebo-controlled trial, we enrolled pati
272                          In this randomized, double-blind, placebo-controlled trial, we investigated
273                                In a phase 2, double-blind, placebo-controlled trial, we randomized 63
274                          In this randomised, double-blind, placebo-controlled trial, we randomly allo
275                         In this multicenter, double-blind, placebo-controlled trial, we randomly assi
276                                      In this double-blind, placebo-controlled trial, we randomly assi
277              In this phase III, multicenter, double-blind, placebo-controlled trial, we randomly assi
278                                      In this double-blind, placebo-controlled trial, we randomly assi
279                    In a phase 2, randomized, double-blind, placebo-controlled trial, we randomly assi
280                                      In this double-blind, placebo-controlled trial, we randomly assi
281                               In our initial double-blind, placebo-controlled trial, we randomly assi
282                                      In this double-blind, placebo-controlled trial, we randomly assi
283                                      In this double-blind, placebo-controlled trial, we randomly assi
284                          In this randomised, double-blind, placebo-controlled trial, we recruited pat
285                             In this phase 3, double-blind, placebo-controlled trial, we recruited pat
286              In a preregistered, randomized, double-blind, placebo-controlled trial, we tested the ef
287                          In this randomized, double-blind, placebo-controlled trial, we treated adult
288          In a pilot prospective, randomized, double-blinded, placebo-controlled trial, we studied whe
289 cipants for this randomised, parallel-group, double-blind, placebo-controlled trial were recruited vi
290       Purpose To determine, in a multicenter double-blinded placebo-controlled trial, whether maximal
291                       This was a randomized, double-blind, placebo-controlled trial with 634 subjects
292                   We performed a randomized, double-blind, placebo-controlled trial with a 12-week ba
293      We performed a multicenter, randomized, double-blind, placebo-controlled trial with Alt a 1 admi
294                We undertook this randomised, double-blind, placebo-controlled trial with four paralle
295                      We now report that in a double-blind, placebo-controlled trial with healthy part
296             We hence conducted a randomized, double-blind, placebo-controlled trial with newly diagno
297                                   This was a double-blind, placebo-controlled trial with subjects ran
298 moprevention (VAKCC) trial was a randomized, double-blinded, placebo-controlled trial with patients f
299       In this multicentre, block-randomised, double-blind, placebo-controlled trial, women aged 18-40
300               In this Phase 4, multi-center, double-blind, placebo-controlled trial, young adults (18

 
Page Top